Mereo BioPharma Group PLC (MREO)
3.72
+0.04
(+1.09%)
USD |
NASDAQ |
Nov 22, 16:00
3.725
0.00 (0.00%)
After-Hours: 20:00
Mereo BioPharma Group Cash from Financing (Quarterly): -0.594M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -0.594M |
| June 30, 2024 | 46.78M |
| March 31, 2024 |
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 7.906M |
| June 30, 2023 | 0.067M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.594M
Minimum
Sep 2024
46.78M
Maximum
Jun 2024
10.83M
Average
0.067M
Median
Jun 2023
Cash from Financing (Quarterly) Benchmarks
| TC BioPharm (Holdings) PLC | 1.183M |
| NuCana PLC | -0.0888M |
| Biodexa Pharmaceuticals PLC | -- |
| Adaptimmune Therapeutics PLC | 25.00M |
| DBV Technologies SA | 0.007M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.519M |
| Free Cash Flow | -30.90M |
| Free Cash Flow Per Share (Quarterly) | -0.0488 |
| Free Cash Flow Yield | -5.76% |